Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia
Lynn R. Webster(Adherent Technologies (United States)), Geertrui F. Vanhove, Margarita Nunez(Comprehensive Clinical Research), Jeffrey Tobias(Jazz Pharmaceuticals (United States)), Biao Lu, Marvin Tark, Edwin Dunteman(Missouri Institute of Mental Health)
Cited by 34
Related Papers
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
|JAMA|2003|958
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309